169281 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing; Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
Compositions for modulating cancer stem cells and uses therefor
#302Biochip for Raman quantitative analysis of biological samples
#303Cancer diagnosis and therapy
#304Cancer vaccine composition
#305PRMT5 inhibitors and uses thereof
#306Screening method
#307PSMA-based molecular-genetic reporter system
#308Selective oxidation of 5-methylcytosine by TET-family proteins
#309Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same
#310Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (EMT) in cancer cells
#311Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
#312Lung cancer adjuvant therapy
#313Method For Predicting Effectiveness Of Angiogenesis Inhibitor
#314Selective oxidation of 5-methylcytosine by TET-family proteins
#315DD1ALPHA RECEPTOR AND USES THEREOF IN IMMUNE DISORDERS
#316Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer
#317Detection of 5-hydroxymethylcytosine by glycosylation
#318SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#319PHARMACODYNAMIC ASSAYS
#320INDIVIDUALIZED CANCER THERAPY
#321SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#322Antibody to mucin 4 (MUC4) glycopeptide and uses thereof
#323Selective oxidation of 5-methylcytosine by TET-family proteins
#324Anti-indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
#325Selective oxidation of 5-methylcytosine by TET-family proteins
#326Method for determining the risk profile of neoplastic tissue
#327STAT5 inhibitors and use thereof
#328Targeted therapeutics
#329SRM/MRM Assay for the Serine/Threonine-Protein Kinase B-RAF (BRAF)
#330Method for the detection of cancer cells by localization of peptides in nucleus as compared to cytoplasm
#331Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion
#332TREATING BAX(DELTA)2-POSITIVE CANCER WITH CHEMOTHERAPIES TARGETING CASPASE 8
#333E1 ENZYME MUTANTS AND USES THEREOF
#334Compositions and methods for treating estrogen-related medical disorders
#335Methods and compositions for assaying blood levels of legumain
#336KERATIN 17 AS A BIOMARKER FOR HEAD AND NECK CANCERS
#337FREE NGAL AS A BIOMARKER FOR CANCER
#338Methods of delivering a polypeptide molecule to Otx2 target cells using an Otx2 targeting peptide
#339Grading of breast cancer
#340Tumor deconstruction platform for the analysis of intra-tumor heterogeneity
#341Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired P53 function
#342METHOD FOR PREDICTING RESPONSE TO THERAPY FOR CANCER
#343Method for diagnosing cancer by detecting C-terminal segment of moesin in blood
#344Endoglin antibodies
#345METHOD FOR TREATING CANCER
#346Fluorocyclopentenylcytosine methods of use
#347Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
#348Methods apparatuses and systems for detecting and quantifying phosphoproteins
#349CANCER VACCINE COMPOSITION
#350THERAPEUTIC AND DIAGNOSTIC METHODS
#351Method of treating MYC-amplified tumors with RNA-polymerase II inhibitors
#352Insulin receptor substrate 1 (IRS1) protein SRM/MRM assay
#353SYSTEM AND METHOD FOR ANALYZING TISSUE INTRA-OPERATIVELY USING MASS SPECTROMETRY
#354Methods for treating cancer
#355Knock-in rodent comprising a mutation in an endogenous CRBN locus and methods of use thereof
#356Methods and kits for isolation and analysis of a chromatin region
#357SRM/MRM assay for the 6-O-methylguanine-DNA methyltransferase (MGMT) protein
#358Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles
#359DRG11-RESPONSIVE (DRAGON) GENE AND USES THEREOF
#360Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
#361ASSAYS AND METHODS FOR CELL PROLIFERATION-TARGETED TREATMENT THERAPIES
#362Kynurenine Pathway Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
#363Methods of treating cancer with atovaquone-related compounds
#364METHOD FOR DETECTINGAND/OR ASSAYING ANNEXIN A3 FROMA MAMMAL IN BLOOD OR AT LEAST ONE DERIVATIVE THEREOF
#365MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS
#366Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
#367COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING HIPPO PATHWAY
#368COMPOSITIONS AND METHODS FOR SELECTING A TREATMENT FOR B-CELL NEOPLASIAS
#369Diagnostic/prognostic marker and therapeutic target for cancer
#370Method for identifying modulators of notch signaling
#371Method for cancer detection, diagnosis and prognosis
#372Akt-specific capture agents, compositions, and methods of using and making
#373Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis
#374ENCAPSULATED SENSORS AND SENSING SYSTEMS FOR BIOASSAYS AND DIAGNOSTICS AND METHODS FOR MAKING AND USING THEM
#375Pyridazinoindole compounds and methods for PET imaging
#376Anti-SOX10 antibody systems and methods
#377Zinc finger linker (ZnFL) antibody
#378DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS
#379Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators
#380Method of measuring cancer related substances by raman spectroscopy
#381Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition
#382Method for predicting cancer sensitivity
#383MPS peptides and use thereof
#384CHARACTERIZATION OF PRE-CANCER BIOMARKER FOR PROGNOSTIC SCREEN
#385Method of Treatment
#386Methods of detecting cancer
#387Imaging tumor glycolysis by non-invasive measurement of pyruvate kinase M2
#388Treating cancer deficient in FANCA, FANCD2, FANCE, or FANCG with an ATM inhibitor
#389Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS
#390Compositions and methods for prognosis and treatment of neoplasm
#391Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
#392Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer
#393METHOD FOR PREDICTING RESPONSE TO CANCER TREATMENT
#394METHOD FOR DIAGNOSING CANCER USING SECRETED RIBOSOMAL PROTEIN S3
#395Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
#396PROGNOSIS AND PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF
#397Method of treating cancer that overexpresses TopBP1
#398PERINUCLEOLAR COMPARTMENT AS A CANCER MARKER
#399Traceability of Cellular Cycle Anomalies Targeting Oncology and Neurodegeneration
#400Anti-DEspR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
#401Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
#402Method for determining prognosis of cancer
#403Method for predicting therapeutic efficacy of PI3K/AKT/mTOR inhibitor on basis of PHLDA1 or PIK3C2B expression
#404Method for detecting nucleosome adducts
#405Method for predicting clinical effect of immunotherapy
#406MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS
#407METHODS AND USES INVOLVING GENETIC ABERRATIONS OF NAV3 AND ABERRANT EXPRESSION OF MULTIPLE GENES
#408RECOVERY OF ASPARTYL (ASPARAGINYL) BETA HYDROXYLASE (HAAH) FROM AN EXOSOMAL FRACTION OF HUMAN SERA FROM CANCER PATIENTS
#409Monoclonal antibody against necrosis marker PRDX4 and use thereof
#410Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
#411IMAGING OF CREATINE KINASE ENZYME EXPRESSION IN CANCEROUS TISSUES
#412Compositions and methods for detecting cancer metastasis
#413Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
#414ANTIBODIES AGAINST ACTIN-BINDING PROTEIN GIRDIN AND METHODS OF MAKING AND USING THE SAME
#415Microvesicle histone H2AX as a biomarker for genotoxic stress
#416Biomarker PNCK for predicting effect of a dual-targeting agent
#417Elisa for VEGF
#418USE OF POLYCLONAL AND MONOCLONAL ANTIBODIES SPECIFIC FOR 3-PHOSPHOHISTIDINE
#419Use of facilitates chromatin transcription complex (FACT) in cancer
#420Biological specimen evaluation methods using cytology and immunology
#421Biomarkers associated with BRM inhibition
#422Companion diagnostic for CDK4 inhibitors
#423Assay
#424METHODS OF CONTROLLING TUMOR BIOENERGETICS NETWORKS
#425Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
#426Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway
#427Replication protein
#428FUSION POLYNUCLEOTIDES AND FUSION POLYPEPTIDES ASSOCIATED WITH CANCER AND PARTICULARLY MELANOMA AND THEIR USES AS THERAPEUTIC AND DIAGNOSTIC TARGETS
#429Antibodies to argininosuccinate synthase and related methods
#430Endoglin antibodies
#431METHODS OF TREATMENT OF CANCER
#432TARGETING GLUTAMINE METABOLISM IN BRAIN TUMORS
#433Reagent for diagnosing tumor, pharmaceutical composition, and screening method
#434Methods of detecting cancer
#435Diagnostic and treatment for chronic and acute phase myeloid leukemia
#436Compositions including triciribine and one or more platinum compounds and methods of use thereof
#437Dominant negative HSP110 mutant and its use in prognosing and treating cancers
#438Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
#439Platelet biomarkers in cancer diagnosis
#440Methods for predicting the survival time of a patient suffering from a solid cancer
#441Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
#442Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
#443INTERFERON TREATMENT TARGETING MUTANT P53 EXPRESSING CELLS
#444ANTIBODY AGAINST THE PROTEIN TRIO AND ITS METHOD OF PRODUCTION
#445BIOMARKERS ASSOCIATED WITH CDK INHIBITORS
#446Inhibition of cancer growth and metastasis
#447Antibody to genetic products differentially expressed in tumors and the use thereof
#448COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH A DEFICIENCY IN THE MRE11/RAD50/NBS1 DNA DAMAGE REPAIR COMPLEX
#449Predictive markers for polyamine inhibitor cancer therapies
#450DIAROMATIC AMINO ACID SUBSTRATE FOR CATHEPSIN DETECTION
#451TREATMENT OF CANCER BY TARGETING QUIESCENT CANCER CELLS
#452Compositions and methods for treating estrogen-related medical disorders
#453iASPP phosphorylation and metastatic potential
#454MATERIALS AND METHODS FOR DETERMINING SUSCEPTIBILITY OR PREDISPOSITION TO CANCER
#455Methods and compositions for use in treatment of FOXP2-related cancers
#456TARGETING CHEMOTHERAPY AGENT RESISTANCE IN CANCER
#457COMPANION DIAGNOSTICS FOR TEC FAMILY KINASE INHIBITOR THERAPY
#458csPCNA Isoform Antibodies And Uses Thereof
#459Method of treating cancer
#460Method for determining the risk profile of neoplastic tissue
#461HSF1 AND HSF1 CANCER SIGNATURE SET GENES AND USES RELATING THERETO
#462DETECTION AND MODULATION OF CYTOCHROME C ACETYLATION
#463Anti-tumour response to modified self-epitopes
#464FERRITIN-BASED TUMOR TARGETING AGENT, AND IMAGING AND TREATMENT METHODS
#465Target peptides for immunotherapy and diagnostics
#466USE OF PROTEIN LINE-1 ORF-1 AS A BIOMARKER FOR CANCER
#467Methods and devices for analyzing species to determine diseases
#468METHODS FOR IDENTIFYING ANTI-CANCER COMPOUNDS
#469DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#470METHODS AND COMPOSITIONS FOR IDENTIFYING, CLASSIFYING AND MONITORING SUBJECT HAVING BCL-2 FAMILY INHIBITOR-RESISTANT TUMORS AND CANCERS
#471Method for detecting CAPRIN-1 in a biological sample
#472FUNCTION AND REGULATION OF ADAMTS-1
#473Method for the isolation of microvesicles
#474Substituted indazoles for targeting Hsp90
#475Compositions Comprising RAC Mutants, and Methods of Use Thereof
#476Method for detecting cancer via measurement of caprin-1 expression level
#477Methods for identifying and treating cancer patients
#478Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
#479TUMOR SUPPRESSOR DESIGNATED TS10Q23.3
#480CIRCULATING TUMOR CELL ASSAY
#481METHOD FOR DETECTING AND/OR ASSAYING ANNEXIN A3 FROM A MAMMAL IN BLOOD OR AT LEAST ONE DERIVATIVE THEREOF
#482Methods and compounds for diagnosing threonyl-tRNA synthetase-associated diseases and conditions
#483METHODS FOR IDENTIFYING AND INHIBITING GROWTH OF CHEMOTHERAPEUTIC-RESISTANT CANCERS
#484METHODS AND COMPOSITIONS FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR-1alpha (PGC1alpha) AS A TARGET OF CIRCULATING TUMOR CELLS
#485Cereblon isoforms and their use as biomarkers for therapeutic treatment
#486BAG3 as biochemical serum and tissue marker
#487Method of diagnosing, treating and determining progression and survival of cancer cells using BCL-2 antagonist of cell death (BAD) pathway gene signature
#488Targeted therapeutics
#489PYRUVATE DEHYROGENASE KINASES AS THERAEUTIC TARGETS FOR CANCER AND ISCHEMIC DISEASES
#490METHOD FOR CHARACTERIZING CIRCULATING TUMOR CELLS, AND USE THEREOF IN DIAGNOSIS
#491IMAGING CELL SORTER
#492RTN4B polypeptide, monoclonal antibody thereof, monoclonal antibody-producing hybridoma cell strain, and, preparation and application thereof
#493Methods related to cancer treatment
#494COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS
#495Methods of detecting Akt3 and administering Ax1 inhibitor
#496DOSE-RESPONSE MEDICAL OUTCOME MODEL PREDICTOR SYSTEM AND METHOD
#497Methods of treating a meiotic kinesin-associated disease
#498PHOSPHOCOFILIN: COFILIN CO-LOCALIZATION INTENSITY AS A PREDICTOR OF METASTATIC RECURRENCE
#499METHOD OF OBTAINING INFORMATION FOR IDENTIFYING TUMOR CELL UNDERGOING EPITHELIAL-MESENCHYMAL TRANSITION IN SAMPLE, METHOD OF IDENTIFYING TUMOR CELL UNDERGOING EPITHELIAL-MESENCHYMAL TRANSITION IN SAMPLE, METHOD OF DIAGNOSING SUBJECT HAVING TUMOR CELL UNDERGOING EPITHELIAL-MESENCHYMAL TRANSITION AND COMPOSITION OR KIT FOR IDENTIFYING TUMOR CELL UNDERGOING EPITHELIAL-MESENCHYMAL TRANSITION IN SAMPLE
#500COMPOSITIONS AND METHODS FOR TREATING CANCER USING INTERFERON AND MAPK PATHWAY INHIBITOR
#501Spalt-like transcription factor 4 (SALL4) and uses thereof
#502ANTI-NEOPLASTIC USES OF ARTEMIN ANTAGONISTS
#503S100A4 antibodies and therapeutic uses thereof
#504BIOMARKERS FOR CANCER CHARACTERIZATION AND TREATMENT
#505BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#506SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS
#507Devices and methods of cell capture and analysis
#508Identification of a JAK2 mutation in polycythemia vera
#509PREDICTIVE BIOMARKER USEFUL FOR CANCER THERAPY MEDIATED BY A CDK INHIBITOR
#510Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
#511CYCLON EXPRESSION FOR THE IDENTIFICATION AND CONTROL OF CANCER CELLS
#512Double-stranded nucleic acid, use and kit thereof in ribonuclease detection
#513POLYPEPTIDES AND POLYNUCLEOTIDES FOR ARTEMIN AND RELATED LIGANDS, AND METHODS OF USE THEREOF
#514METHODS AND SYSTEMS OF USING BIOMARKERS FOR DETERMINING PHENOTYPES
#515Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers
#516METHODS FOR ASSESSING RISK FOR CANCER USING BIOMARKERS
#517BIN1 expression as a marker of cancer
#518Phosphorylation of histones and uses thereof
#519Cell death assay
#520Anti-IGF antibodies
#521PREDICTIVE BIOMARKER FOR HYPOXIA-ACTIVATED PRODRUG THERAPY
#522Protein target complex
#523Biomarker and Uses Thereof
#524METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY IN A SUBJECT WITH CANCER
#525BIOMARKERS OF MIR-34 ACTIVITY
#526Methods of treating cancer
#527Cleavage inhibitors of transforming growth factor beta type I receptor and uses thereof in cancer therapy
#528METHODS AND COMPOSITIONS TO DETECT THE LEVEL OF LYSOSOMAL EXOCYTOSIS ACTIVITY AND METHODS OF USE
#529GENE EXPRESSION SIGNATURES FOR STAGING AND PROGNOSIS OF PROSTATE, BREAST AND LEUKEMIA CANCERS
#530METHODS AND COMPOUNDS FOR DETECTING CANCER
#531MARKER FOR DETECTING COLORECTAL CANCER OR ESOPHAGEAL CANCER AND METHOD FOR EXAMINING SUCH CANCER
#532Methods for suppressing cancer by inhibition of TMCC3
#533HISTONE DEACETYLASE (HDAC) BIOMARKERS IN MULTIPLE MYELOMA
#534HE4 based therapy for malignant disease
#535ALK and NTRK1 fusion molecules and uses thereof
#536METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS
#537HISTONE DEACETYLASE 10-INHIBITOR CO-TREATMENT IN CANCER
#538B7-H1 AND SURVIVIN IN CANCER
#539Monoclonal antibody specifically recognizing asparagine synthetase
#540Method for detecting nucleosome adducts
#541Cancer diagnostic and cancer therapeutic
#542METHODS OF DIAGNOSING CANCER IN A PATIENT
#543Endoglin antibodies
#544Mutations of histone proteins associated with proliferative disorders
#545Glycosylation site-specific antibodies and anti-cancer compounds
#546Diagnostic and Prognostic Markers for Cancer
#547ANTI-CMET ANTIBODY AND ITS USE FOR THE DETECTION AND THE DIAGNOSIS OF CANCER
#548Novel Method of Cancer Diagnosis and Prognosis and Prediction of Response to Therapy
#549FUNCTION AND REGULATION OF ADAMTS-1
#550METHODS AND COMPOSITIONS FOR PREDICTING RESISTANCE TO ANTICANCER TREATMENT
#551Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
#552Giant obscurins and uses thereof in cancer prognosis and therapy
#553NOVEL RETROELEMENT FOUND IN MOLLUSKS
#554VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS
#555WNT4 AND MED12 FOR USE IN THE DIAGNOSIS AND TREATMENT OF TUMOR DISEASES
#556Antibody against mutant α-actinin-4
#557FREE NGAL AS A BIOMARKER FOR CANCER
#558Methods and compositions for cytometric detection of rare target cells in a sample
#559KRT19 stabilizing HER2 and use thereof
#560ZNF365/ZFP365 biomarker predictive of anti-cancer response
#561CANCER BIOMARKER AND METHODS OF USE THEREOF
#562Target of the phosphoinositide 3-kinase pathway
#563HSF1 as a marker in tumor prognosis and treatment
#564USE OF CCNE2 AS A STRATIFICATION MARKER IN THE TREATMENT OF BREAST TUMOURS WITH NOVEL PAN-CDK INHIBITORS
#565COMPUTER-IMPLEMENTED SYSTEM AND METHOD FOR THE PREDICTION OF CANCER RESPONSE TO GENOTOXIC CHEMOTHERAPY AND PERSONALISED NEOADJUVANT TREATMENTS (PCCP)
#566Method of treating hyperproliferation of cells using a nucleolin specific aptamer
#567METHODS OF DIAGNOSING CANCER USING EPIGENETIC BIOMARKERS
#568METHODS, APPARATUSES, AND SYSTEMS FOR DETECTING AND QUANTIFYING PHOSPHOPROTEINS
#569Stratification of pancreatic and ovarian cancer patients for susceptibility to therapy with PTK2 inhibitors
#570Methods and Compositions for the Diagnosis and Treatment of Epithelial Cancers
#571MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR
#572Reagent for diagnosing tumor, pharmaceutical composition, and screening method
#573METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A NOVEL MTOR COMPLEX
#574Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
#575Methods of treating a meiotic kinesin associated disease
#576Use of LRIG1 as a biomarker for identifying a subject for application of anti-c-Met antibodies
#577Method of diagnosing cancer using a nucleolin specific aptamer
#578DIAGNOSIS AND PROGNOSIS OF TRIPLE NEGATIVE BREAST AND OVARIAN CANCER
#579TARGETED THERAPEUTICS
#580Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors
#581Compositions and methods for the treatment of cancer
#582Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles
#5835-hydroxymethylcytosine in human cancer
#584Method and apparatus for analyzing cells
#585LOSS OF 5-HYDROXYMETHYLCYTOSINE AS A BIOMARKER FOR CANCER
#586Markers for identifying breast cancer treatment modalities
#587Method for Detecting a Target Analyte Using a Self-Cleaving Synthetic Molecule
#588Antibody conjugates against variant NFKBIB and uses thereof
#589Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
#590Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
#591Method of judging risk of cancer recurrence and computer program
#592PROGNOSTIC AND/OR PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF
#593METHOD FOR INDUCING CELL SENESCENCE BY RECOMBINANT INTERFERON WITH ALTERED SPATIAL CONFIGURATION
#594Tyrosine-phosphorylated WBP2, a novel cancer target and biomarker
#595METHODS FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A SOLID CANCER
#596Identification of a JAK2 mutation involved in vaquez polyglobulia
#597Predictive markers for taxane responsiveness and methods of use thereof
#598Methods and Kits for Detecting Circulating Cancer Stem Cells
#599Methods for identifying and validating selective anti-cancer stem cell agents
#600PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY